These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24803435)

  • 1. Randomized comparison between polymer-free versus polymer-based paclitaxel-eluting stent: two-year final clinical results.
    Shiratori Y; Cola C; Brugaletta S; Alvarez-Contreras L; Martín-Yuste V; del Blanco BG; Ruiz-Salmeron R; Díaz J; Pinar E; Martí V; García-Picart J; Sabaté M
    Circ Cardiovasc Interv; 2014 Jun; 7(3):312-21. PubMed ID: 24803435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial.
    King L; Byrne RA; Mehilli J; Schömig A; Kastrati A; Pache J
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):E23-8. PubMed ID: 22431239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six-month angiographic and one-year clinical outcomes of polymer free paclitaxel-eluting stent in patients with ST-segment elevation myocardial infarction: a comparison with permanent polymer sirolimus-eluting stent.
    Dang Q; Li YJ; Gao L; Jin Z; Gou LX
    Chin Med J (Engl); 2012 Oct; 125(19):3393-7. PubMed ID: 23044294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
    Waseda K; Miyazawa A; Ako J; Hasegawa T; Tsujino I; Sakurai R; Yock PG; Honda Y; Kandzari DE; Leon MB; Fitzgerald PJ;
    JACC Cardiovasc Interv; 2009 Aug; 2(8):779-84. PubMed ID: 19695548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus: the LIPSIA Yukon trial.
    Desch S; Schloma D; Möbius-Winkler S; Erbs S; Gielen S; Linke A; Yu J; Lauer B; Kleinertz K; Dänschel W; Schuler G; Thiele H
    JACC Cardiovasc Interv; 2011 Apr; 4(4):452-9. PubMed ID: 21511226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Mahaffey KW; Cutlip DE; Fitzgerald PJ; Sood P; Su X; Lansky AJ;
    JAMA; 2008 Apr; 299(16):1903-13. PubMed ID: 18430909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravascular ultrasound results from the NEVO ResElution-I trial: a randomized, blinded comparison of sirolimus-eluting NEVO stents with paclitaxel-eluting TAXUS Liberté stents in de novo native coronary artery lesions.
    Otake H; Honda Y; Courtney BK; Shimohama T; Ako J; Waseda K; Macours N; Rogers C; Popma JJ; Abizaid A; Ormiston JA; Spaulding C; Cohen SA; Fitzgerald PJ
    Circ Cardiovasc Interv; 2011 Apr; 4(2):146-54. PubMed ID: 21386089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term clinical outcomes after everolimus- and sirolimus-eluting coronary stent implantation: final 3-year follow-up of the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial.
    Shiomi H; Kozuma K; Morimoto T; Igarashi K; Kadota K; Tanabe K; Morino Y; Akasaka T; Abe M; Suwa S; Muramatsu T; Kobayashi M; Dai K; Nakao K; Uematsu M; Tarutani Y; Fujii K; Simonton CA; Kimura T;
    Circ Cardiovasc Interv; 2014 Jun; 7(3):343-54. PubMed ID: 24803436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of biolimus A9-eluting (Nobori) and everolimus-eluting (Promus Element) stents in patients with de novo native long coronary artery lesions: a randomized Long Drug-Eluting Stent V trial.
    Lee JY; Park DW; Kim YH; Ahn JM; Kim WJ; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Yang TH; Lee BK; Lee NH; Yang JY; Shin WY; Park HS; Kim KS; Hur SH; Lee SY; Park JS; Choi YS; Lee SU; Her SH; Park SJ
    Circ Cardiovasc Interv; 2014 Jun; 7(3):322-9. PubMed ID: 24823426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strut coverage and vessel wall response to a new-generation paclitaxel-eluting stent with an ultrathin biodegradable abluminal polymer: Optical Coherence Tomography Drug-Eluting Stent Investigation (OCTDESI).
    Guagliumi G; Sirbu V; Musumeci G; Bezerra HG; Aprile A; Kyono H; Fiocca L; Matiashvili A; Lortkipanidze N; Vassileva A; Popma JJ; Allocco DJ; Dawkins KD; Valsecchi O; Costa MA
    Circ Cardiovasc Interv; 2010 Aug; 3(4):367-75. PubMed ID: 20647562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent.
    Haude M; Lee SW; Worthley SG; Silber S; Verheye S; Erbs S; Rosli MA; Botelho R; Meredith I; Sim KH; Stella PR; Tan HC; Whitbourn R; Thambar S; Abizaid A; Koh TH; Den Heijer P; Parise H; Cristea E; Maehara A; Mehran R
    JACC Cardiovasc Interv; 2013 Apr; 6(4):334-43. PubMed ID: 23523459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Edge vascular response after polymer-free vs. polymer-based paclitaxel-eluting stent implantation.
    Otsuki S; Shiratori Y; Brugaletta S; Cola C; García Del Blanco B; Ruiz-Salmeron R; Díaz JF; Pinar E; Martí V; García-Picart J; Martín-Yuste V; Sabaté M
    Circ J; 2014; 78(11):2657-64. PubMed ID: 25241887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a double-coated paclitaxel-eluting coronary stent: the EUCATAX trial.
    Rodriguez AE; Vigo CF; Delacasa A; Mieres J; Fernandez-Pereira C; Bernardi V; Bettinoti M; Rodriguez-Granillo AM; Rodriguez-Granillo G; Santaera O; Curotto V; Rubilar B; Tronge J; Palacios IF; Antoniucci D;
    Catheter Cardiovasc Interv; 2011 Feb; 77(3):335-42. PubMed ID: 20824769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2.
    Chevalier B; Silber S; Park SJ; Garcia E; Schuler G; Suryapranata H; Koolen J; Hauptmann KE; Wijns W; Morice MC; Carrie D; van Es GA; Nagai H; Detiege D; Paunovic D; Serruys PW;
    Circ Cardiovasc Interv; 2009 Jun; 2(3):188-95. PubMed ID: 20031715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
    Kirtane AJ; Patel R; O'Shaughnessy C; Overlie P; McLaurin B; Solomon S; Mauri L; Fitzgerald P; Popma JJ; Kandzari DE; Leon MB
    JACC Cardiovasc Interv; 2009 Oct; 2(10):967-76. PubMed ID: 19850257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.